No insider purchase over the last 90 days. The latest, by 김이랑, was filed 12 Jun 2026.
Oncocross Co., Ltd.: what insiders have been doing
This page follows insider dealings at Oncocross Co., Ltd. as filed with DART (FSS), a company from the Technology sector. In the past year (31 October 2025 to 31 October 2026), 13 filings came from 6 insiders.
The record shows 6 purchases on the open market, made by 4 insiders, against 3 sales by 3 insiders. The amount is not disclosed for 9 filings. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. On the buying side, the filings list 1 major shareholder and 1 board member among the declarants.
The clock since the last published purchase (12 June 2026) now reads 150 days. Between a trade and the moment it shows up on DART (FSS), the median delay is 6 days. The shorter that gap, the sooner other investors can see what insiders have done.
With 13 filings in twelve months, the company is more active than the median of 7 filings across the 2,655 companies we follow on the same exchange. Since 2024, the database holds 15 purchases and 7 sales by insiders of the company.
In the same sector, recent insider purchases at Basler Aktiengesellschaft and Lime Technologies AB (publ) also feature in our signals. This summary is built from DART (FSS) disclosures alone and does not predict where the share price will go.
Who traded when
BuySale+1 other insider
Since the insiders bought
- -61.7%Entry ₩7,510 · Close 30 Oct 2026 ₩2,875
- -60.9%Entry ₩7,350 · Close 30 Oct 2026 ₩2,875
- -69.8%Entry ₩9,510 · Close 30 Oct 2026 ₩2,875
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- Other0DART
- ●Executives0DART
- 11,256 sharesKRXDART:20260612000315Canonical exit: 10 Sept 2026 (T+90)
- 30,000 sharesShareKRXDART:20260427000743
- 278,200 sharesKRXDART:20260407003153Canonical exit: 29 Jun 2026 (T+90)
- 3,320,069 sharesKRXDART:20260323001428
- ●Executives0DART
- 18,000 sharesShareKRXDART:20260227008536
- 181,806 sharesKRXDART:20260226007196Canonical exit: 26 May 2026 (T+90)
- ShareKRXDART:20260213002572
- 786,988 sharesKRXDART:20260203000204Canonical exit: 30 Apr 2026 (T+90)
- 18,000 sharesShareKRXDART:20260128000459Canonical exit: 28 Apr 2026 (T+90)
- ShareKRXDART:20260128000423
- 1,204,209 sharesKRXDART:20251224000708Canonical exit: 18 Mar 2026 (T+90)
- 244,816 sharesKRXDART:20250425000784
- 398,364 sharesKRXDART:20250203000291
- 8,284,778 sharesKRXDART:20250203000279Canonical exit: 18 Mar 2025 (T+90)
- 398,364 sharesKRXDART:20250131000475
- 8,294,691 sharesKRXDART:20250131000451Canonical exit: 18 Mar 2025 (T+90)
- 508,810 sharesKRXDART:20241226000556Canonical exit: 18 Mar 2025 (T+90)
- 80,808 sharesShareKRXDART:20241226000435Canonical exit: 26 Mar 2025 (T+90)
- 2,052,000 sharesShareKRXDART:20241226000419Canonical exit: 26 Mar 2025 (T+90)
- 1,204,209 sharesKRXDART:20241226000408Canonical exit: 18 Mar 2025 (T+90)
- 165,513 sharesKRXDART:20241223000165
- 662,052 sharesKRXDART:20241219000340Canonical exit: 18 Mar 2025 (T+90)
25 of 27 declarations
About Oncocross Co., Ltd.
온코크로스 is a technology company listed on the XKRX. It specializes in developing innovative solutions for the healthcare sector.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
